Navigation Links
Safety data favor norepinephrine over dopamine for shock
Date:3/3/2010

ATLANTA - Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

Jerrold Levy, MD, FAHA, professor and deputy chair for research, Department of Anesthesiology, Emory University School of Medicine, and co-director of cardiothoracic anesthesiology, Emory Healthcare, authored the editorial.

The editorial accompanies a report in the same issue of NEJM on a European clinical trial evaluating dopamine and norepinephrine in shock patients. The randomized trial, led by Daniel De Backer, MD, PhD, at Erasme University Hospital in Belgium, compared 28-day mortality in 1679 patients treated for shock with dopamine or norepinephrine in Austria, Belgium and Spain between 2003 and 2007.

"Dopamine has been commonly used as a first-line therapy for shock at many hospitals for years, partially because of the widespread perception that norepinephrine is associated with adverse events," Levy says. "The current study supports the concept that shock from any cause carries a high risk of death, and raises significant concerns about the safety of dopamine."

Shock, or dangerously low blood pressure, can occur as a result of sepsis (severe inflammation resulting from bacterial infection), heart failure (cardiogenic), hemorrhage (severe blood loss) or anaphylaxis. Most of the patients (62.2 percent) in the European trial had septic shock, 16.7 percent had heart failure and 15.7 percent hemorrhage.

The authors of the clinical study reported no overall difference in death rates at 28 days. However, heart arrhythmias were almost twice as common in the dopamine group (24.1 percent vs 12.4 percent) and mortality was higher for patients with cardiogenic shock treated with dopamine.

A previous observational study showed that dopamine's use in intensive care units added to the risk of death, and rapid heart rate is known to be a frequent side effect of dopamine, Levy notes.

Norepinephrine has been used to stabilize patients' blood pressure during cardiac and non cardiac surgery, and in intensive care units after surgery. Vasopressin, although not studied in the European clinical trial, is also a viable alternative treatment for shock, Levy says.

The hormones dopamine and norepinephrine have functions in the brain, helping neurons communicate, as well as in the body to maintain vascular tone. In an emergency situation, they both can increase blood pressure by constricting blood vessels. Dopamine is the precursor to norepinephrine in the sympathetic nervous system, and thus acts indirectly.

"The data challenge consensus guidelines that recommend dopamine as the initial vasopressor for increasing arterial pressure in the case of septic shock or cardiogenic shock," Levy writes in the editorial.

"In addition, norepinephrine needs to be considered as an initial therapeutic agent for patients in circulatory shock. The results of the study by De Backer et al should also put an end to the outdated view that the use of norepinephrine increases the risk of death."


'/>"/>

Contact: Lance Skelly
lskelly@emory.edu
404-686-8538
Emory University
Source:Eurekalert

Related medicine news :

1. FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs
2. MainStreet MD Launches Personal Safety Solutions for Children and Seniors Built On SensorLogic's Cloud Computing Platform
3. Brain Injury Association of Washington Provides National Leadership in Concussion Safety & Awareness
4. Occupational Health Expert Expands PureSafety's Growing Strategic Resources Team
5. Surgical Information Systems Introduces SIS OR View to Maximize Communication and Improve Patient Safety in the Operating Room
6. Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records
7. American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages
8. Toyota Recalls Raise Awareness of Vehicle Safety Issues, Risks of Accidents from Driving Defective Automobiles
9. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
10. Bitrex Bitter Safety Additive Exhibiting at the Safe Kids Fair 2010; Making a Bitter Face to Learn about Poisoning Prevention
11. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in women's ... loss. Although hair transplant procedures can be seen as more of a man’s issue, ... two reasons a woman may see her hair thinning. , “We are used to ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended Capio Partners ... This event was exclusive to providers and offered an opportunity to collaborate and network ... the Manchester Grand Hyatt where attendees gathered for a lively discussion on trends and ...
(Date:3/28/2017)... ... ... a thrilling adventure that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the ... had asked of him that he had neglected to do, but this was from God ... were some who would have felt themselves to be special and better than others due ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
(Date:3/27/2017)... March 27, 2017 Medtec ... and more than 600 exhibitors from 70 countries ... and solutions that will advance the medical technology ... at the Messe Stuttgart, Stuttgart, Germany ... technology platform showcasing the key trends and insights ...
(Date:3/27/2017)... , March 27, 2017  A new ... (AADE) found that Medicare,s Competitive Bidding Program (CBP) significantly ... testing supplies. The lack of choice forces beneficiaries to ... have dire health consequences. AADE,s survey ... by AADE and others pointing out the inherent problems ...
Breaking Medicine Technology: